{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:12Z","timestamp":1792269492045,"version":"4.4.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Enzalutamide combined with docetaxel is one of the effective therapeutic regimens for metastatic castration-resistant prostate cancer (mCRPC), which significantly prolongs progression-free survival (PFS). For mCRPC patients with bone marrow metastasis (BMM), bone marrow metastasis itself impairs the bone marrow microenvironment and results in reduced hematopoietic function. The combined therapy may induce life-threatening refractory thrombocytopenia, which has been rarely reported in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 62-year-old male patient with mCRPC and confirmed bone marrow metastasis was reported herein. After progression to mCRPC, the patient was treated with enzalutamide plus docetaxel, followed by grade 4 refractory thrombocytopenia. The lowest platelet count decreased to 3\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L, and the patient showed poor response to conventional supportive care. Bone marrow biopsy confirmed progressive infiltration of tumor cells in the bone marrow with occasional megakaryocytes. Docetaxel and enzalutamide were discontinued, and platelet transfusion and subcutaneous injection of recombinant human thrombopoietin were administered. The hemorrhagic manifestations were relieved, while platelet count remained persistently low.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Enzalutamide combined with docetaxel may increase the risk of refractory grade 4 thrombocytopenia among mCRPC patients with bone marrow infiltration, as illustrated by this single clinical case.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1863480","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:01Z","timestamp":1788150481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Refractory thrombocytopenia induced by enzalutamide combined with docetaxel chemotherapy in a metastatic castration-resistant prostate cancer patient with bone marrow metastasis: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yong","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urology, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, West China School of Medicine, Sichuan University, Sichuan University Affiliated Chengdu Second People\u2019s Hospital, Chengdu Second People\u2019s Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00560-5","article-title":"Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study","volume":"23","author":"Merseburger","year":"2022","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1361596","article-title":"Protection of neutrophils by bone marrow mesenchymal stromal cells is enhanced by tumor-associated inflammatory cytokines","volume":"15","author":"Liang","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70037","article-title":"Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven approaches","volume":"131","author":"Saeed","year":"2025","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104248","article-title":"Comprehensive review of solid tumor bone marrow metastasis","volume":"194","author":"Zhang","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216468","article-title":"Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of T\u03b2RI expression","volume":"579","author":"Alsamraae","year":"2023","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00514-9","article-title":"Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada","volume":"26","author":"Shayegan","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2021.06.016","article-title":"Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial","volume":"155","author":"Caffo","year":"2021","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6552","article-title":"Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial","volume":"10","author":"Dai","year":"2024","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.002","article-title":"A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial","volume":"175","author":"Climent","year":"2022","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-212567","article-title":"Continuous use of enzalutamide in a patient who developed enzalutamide-induced thrombocytopenia","volume":"2","author":"Sato","year":"2015","journal-title":"BMJ Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4255","article-title":"Biweekly vs triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer: The CABASTY phase 3 randomized clinical trial","volume":"9","author":"Oudard","year":"2023","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic Malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279484","article-title":"Treatment of drug-induced immune thrombocytopenias","volume":"107","author":"Marini","year":"2022","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35292","article-title":"A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study","volume":"130","author":"Chen","year":"2024","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/iju5.12025","article-title":"Enzalutamide-induced severe thrombocytopenia complicated by a seizure in a 76-year-old man with castration-resistant prostate cancer","volume":"2","author":"Murata","year":"2019","journal-title":"IJU Case Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0b013e3181cea0b3","article-title":"Docetaxel-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome-related complex in a patient with metastatic prostate cancer","volume":"18","author":"Shrestha","year":"2011","journal-title":"Am J Ther"},{"key":"B20","article-title":"A case of lung cancer associated with drug-induced immune thrombocytopenia","volume":"44","author":"Yamane","year":"2017","journal-title":"Gan To Kagaku Ryoho"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107589","article-title":"Unraveling the pathogenesis of bone marrow hematopoietic injury and the therapeutic potential of natural products","volume":"212","author":"Long","year":"2025","journal-title":"Pharmacol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s13046-022-02520-0","article-title":"Osteoblasts and osteoclasts: an important switch of tumour cell dormancy during bone metastasis","volume":"41","author":"Dai","year":"2022","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1863480\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:02Z","timestamp":1788150482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1863480\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1863480"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1863480","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1863480"}}